Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech/Biogen Idec Second Generation Anti-CD20 Marriage May Be On The Rocks

This article was originally published in The Pink Sheet Daily

Executive Summary

Dispute over rights to second generation anti-CD20 molecules could have a negative impact on development timelines, Genentech says.

You may also be interested in...



Biogen Idec Accelerates Development Of Rheumatoid Arthritis Candidate On Phase IIa Data

Company has initiated trials of the lymphotoxin beta fusion protein in two key RA patient populations.

Biogen Idec Accelerates Development Of Rheumatoid Arthritis Candidate On Phase IIa Data

Company has initiated trials of the lymphotoxin beta fusion protein in two key RA patient populations.

Genentech Alerts Of Tracheoesophageal Fistula Risk In Avastin Trial

Company is updating FDA about emerging risk of tracheoesophageal fistula in small cell lung cancer patients treated with Avastin.

Related Content

Topics

UsernamePublicRestriction

Register

PS065801

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel